For General Information, page-2671

it’s a brand new company, and I think we need to hang up the past concerns and judge it on current performance/actions. Really the only old guard still there is George and that’s an absolute blessing given his contributions, knowledge and ability.

James even addressed some of the past failings, and highlighted the oversight to not engage heavily with physicians and patients advocacy groups, which he will now do as a priority He spoke to how important these groups can be to the overall FDA process.

Walked away from that update feeling very happy that we have the right people in place. Now it’s down to the science, so it’s time to wait and stop watching the daily blips.